Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 726,979 shares of the biopharmaceutical company’s stock after selling 32,851 shares during the period. Corient Private Wealth LLC owned about 0.06% of Gilead Sciences worth $58,893,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SteelPeak Wealth LLC acquired a new stake in shares of Gilead Sciences in the third quarter worth $1,729,000. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in Gilead Sciences during the third quarter valued at about $1,189,000. Larson Financial Group LLC boosted its holdings in Gilead Sciences by 15.0% during the third quarter. Larson Financial Group LLC now owns 1,199 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 156 shares during the period. Nomura Asset Management Co. Ltd. boosted its holdings in Gilead Sciences by 3.6% during the third quarter. Nomura Asset Management Co. Ltd. now owns 892,113 shares of the biopharmaceutical company’s stock valued at $66,855,000 after acquiring an additional 31,032 shares during the period. Finally, STF Management LP boosted its holdings in Gilead Sciences by 156.5% during the third quarter. STF Management LP now owns 20,388 shares of the biopharmaceutical company’s stock valued at $1,528,000 after acquiring an additional 12,438 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Barclays decreased their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, Mizuho decreased their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $83.69.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

Shares of NASDAQ GILD traded up $0.16 during midday trading on Wednesday, reaching $67.45. 294,073 shares of the stock were exchanged, compared to its average volume of 7,207,923. The business has a 50-day simple moving average of $68.93 and a two-hundred day simple moving average of $74.75. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a market capitalization of $84.03 billion, a price-to-earnings ratio of 186.92, a P/E/G ratio of 1.37 and a beta of 0.22. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.37 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.57%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.